RPS6KA5 (Ab-564) Antibody

What is RPS6KA5 and what is its biological significance?

RPS6KA5, also known as MSK1 (Mitogen and Stress-activated protein Kinase 1), is a serine/threonine protein kinase belonging to the AGC family of kinases, structurally related to the ribosomal p70 S6 kinase subfamily . This approximately 90 kDa protein plays critical roles in signal transduction pathways, specifically within the MAPK/ERK and calcium signaling pathways . RPS6KA5 functions as a nexus in cellular responses to mitogens and stress stimuli, phosphorylating multiple targets including transcription factors and histones.

The biological significance of RPS6KA5 is extensive and multifaceted. It is required for the mitogen or stress-induced phosphorylation of transcription factors CREB1 and ATF1 . Additionally, it regulates other transcription factors including RELA, STAT3, and ETV1/ER81 . RPS6KA5 contributes to gene activation through histone phosphorylation, particularly by phosphorylating 'Ser-10' of histone H3 in response to mitogenic or stress stimuli, resulting in the transcriptional activation of immediate early genes, including proto-oncogenes c-fos/FOS and c-jun/JUN .

What are the key specifications of the RPS6KA5 (Ab-564) Antibody?

The RPS6KA5 (Ab-564) Antibody is a polyclonal antibody produced in rabbits that specifically targets human RPS6KA5 protein . Based on the product information available:

This antibody detects endogenous levels of MSK1 protein in the region surrounding Met355 .

What is the optimal protocol for using RPS6KA5 (Ab-564) Antibody in Western blotting?

For optimal Western blot results with the RPS6KA5 (Ab-564) Antibody, I recommend the following protocol based on validated methods:

• Sample Preparation:

  • Prepare cell/tissue lysates using a buffer containing protease and phosphatase inhibitors

  • Determine protein concentration using Bradford or BCA assay

  • Denature 20-50 μg of protein at 95°C for 5 minutes in Laemmli buffer

• Gel Electrophoresis and Transfer:

  • Separate proteins on a 10% SDS-PAGE gel (appropriate for the ~90 kDa RPS6KA5 protein)

  • Transfer to a PVDF membrane at 100V for 90 minutes at 4°C

• Blocking and Antibody Incubation:

  • Block membrane with 5% non-fat milk or BSA in TBST for 1 hour at room temperature

  • Incubate with RPS6KA5 (Ab-564) Antibody at a dilution of 1:500 to 1:3000 in blocking buffer overnight at 4°C

  • Wash 3x with TBST, 5 minutes each

  • Incubate with HRP-conjugated secondary antibody for 1 hour at room temperature

  • Wash 3x with TBST, 5 minutes each

• Detection:

  • Develop using ECL reagent and image using chemiluminescence detection system

Based on product validation data, this antibody should detect a band at approximately 90 kDa representing RPS6KA5 . Western blot analysis demonstrated successful detection in extracts from Jurkat cells and JK cells, with signal specificity confirmed through peptide competition assays .

How can I validate the specificity of the RPS6KA5 (Ab-564) Antibody in my experimental system?

Validating antibody specificity is crucial for ensuring reliable experimental results. For the RPS6KA5 (Ab-564) Antibody, consider these validation approaches:

• Peptide Competition Assay:

  • Pre-incubate the antibody with the immunizing peptide (synthesized peptide derived from C-terminal of human SHP-1)

  • In parallel, use the antibody without peptide competition

  • Compare Western blot results - signal should be significantly reduced in the peptide-competed sample

• Genetic Knockdown/Knockout Controls:

  • Use siRNA, shRNA, or CRISPR/Cas9 to reduce or eliminate RPS6KA5 expression

  • Compare antibody signal between control and knockdown/knockout samples

  • A specific antibody will show reduced signal corresponding to the level of knockdown

• Positive and Negative Control Cell Lines:

  • Use Jurkat cells as a positive control (shown to express detectable levels of RPS6KA5)

  • Include cell lines known to have low/no expression of RPS6KA5 as negative controls

• Molecular Weight Verification:

  • Confirm that the detected band appears at the expected molecular weight (~90 kDa)

  • Verify with multiple detection methods (chemiluminescence, fluorescence)

• Cross-Reactivity Assessment:

  • If working with non-human samples, verify species cross-reactivity

  • Test for potential cross-reactivity with other RSK family members

The product data shows that peptide competition effectively eliminated the signal in Western blot analysis, providing strong evidence for antibody specificity .

How can the RPS6KA5 (Ab-564) Antibody be used to investigate MAPK pathway dysregulation in disease models?

The RPS6KA5 (Ab-564) Antibody provides a valuable tool for investigating MAPK pathway dysregulation in various disease models, particularly in neurodevelopmental disorders where this pathway shows significant alterations . Here's a methodological approach:

• Baseline Expression Analysis:

  • Compare RPS6KA5 expression levels between control and disease model samples using Western blotting with quantitative densitometry

  • Normalize to appropriate housekeeping proteins (β-actin, GAPDH) and calculate relative expression values

• Phosphorylation Status Assessment:

  • Since RPS6KA5 activation requires phosphorylation at specific residues (Thr581 and Ser360), use phospho-specific antibodies alongside the RPS6KA5 (Ab-564) Antibody

  • Calculate phospho-to-total RPS6KA5 ratios to determine activation status

• Subcellular Localization Studies:

  • Use immunofluorescence with the RPS6KA5 (Ab-564) Antibody to track subcellular localization in response to stimuli

  • Nuclear translocation often indicates activation and can be quantified through nuclear/cytoplasmic signal ratios

• Downstream Target Analysis:

  • Examine phosphorylation of RPS6KA5 substrates including CREB1, ATF1, histone H3 (Ser10), and HMGN1

  • This provides functional readouts of RPS6KA5 activity in the disease model

• Pathway Integration Studies:

  • Combine with antibodies against upstream MAPK pathway components (ERK1/2, p38)

  • Implement pathway inhibitor studies (using U0126 for MEK/ERK inhibition) to confirm specificity

This approach is particularly relevant for disorders like Fragile X syndrome and Down syndrome, where gene expression changes in the MAPK/ERK pathway have been documented . The RPS6KA5 (Ab-564) Antibody enables detection of both expression changes and functional alterations in this pathway.

What considerations should be made when using RPS6KA5 (Ab-564) Antibody for immunohistochemistry on tissue sections?

When using RPS6KA5 (Ab-564) Antibody for immunohistochemistry (IHC) on paraffin-embedded tissue sections, several methodological considerations should be addressed:

• Antigen Retrieval Optimization:

  • Heat-induced epitope retrieval (HIER) is recommended using citrate buffer (pH 6.0) or EDTA buffer (pH 9.0)

  • Test both methods to determine optimal antigen retrieval for specific tissue types

  • Typical protocol: 20 minutes at 95-100°C in retrieval buffer

• Antibody Dilution Determination:

  • The recommended dilution range for IHC is 1:50-1:200

  • Perform a dilution series to determine optimal concentration for your specific tissue type

  • Include positive control tissues known to express RPS6KA5

• Signal Amplification Considerations:

  • For weakly expressed targets, consider using polymer-based detection systems or tyramide signal amplification

  • Biotin-based detection systems may require biotin blocking to reduce background

• Counterstaining and Controls:

  • Use hematoxylin for nuclear counterstaining to provide tissue context

  • Include negative controls (primary antibody omission, isotype controls)

  • Include positive controls (tissues with known RPS6KA5 expression)

• Tissue-Specific Considerations:

  • Brain tissue: RPS6KA5 plays important roles in neuronal signaling, so optimize protocols for neuronal preservation

  • Immune tissues: Consider the role of RPS6KA5 in inflammatory responses when interpreting results in these tissues

• Dual Labeling Opportunities:

  • Consider combining with phospho-specific antibodies to correlate RPS6KA5 expression with activation status

  • Dual labeling with cell-type specific markers helps identify which cell populations express RPS6KA5

The recommended starting protocol involves 1:100 dilution with overnight incubation at 4°C following heat-mediated antigen retrieval, but optimization for specific tissues is essential.

How can I design experiments to investigate the role of RPS6KA5 in histone modification and transcriptional regulation?

RPS6KA5 plays a significant role in histone modification and transcriptional regulation, particularly through phosphorylation of histone H3 at Ser10 and potentially Ser28 . To investigate these functions:

• Chromatin Immunoprecipitation (ChIP) Assays:

  • Use antibodies against phosphorylated histone H3 (Ser10) alongside RPS6KA5 (Ab-564) Antibody

  • Design primers for immediate early genes known to be regulated by RPS6KA5 (c-fos, c-jun)

  • Compare ChIP signals between control and stimulated conditions (e.g., serum stimulation, stress induction)

  • Protocol recommendation: Fix cells with 1% formaldehyde, sonicate to generate 200-500bp fragments, and use 2-5μg antibody per IP reaction

• Sequential ChIP (Re-ChIP):

  • First ChIP with histone H3 (phospho-Ser10) antibody

  • Second ChIP with RPS6KA5 (Ab-564) Antibody

  • This approach identifies genomic regions where both proteins co-localize

• Reporter Gene Assays:

  • Construct luciferase reporters containing promoters of RPS6KA5-regulated genes

  • Co-transfect with RPS6KA5 expression constructs (wild-type and kinase-dead mutants)

  • Measure luciferase activity to assess transcriptional impact

  • Include appropriate controls (empty vector, unrelated kinase)

• Co-Immunoprecipitation (Co-IP) Studies:

  • Use RPS6KA5 (Ab-564) Antibody to immunoprecipitate endogenous protein

  • Probe for interacting transcription factors (CREB1, ATF1, RELA, STAT3, ETV1)

  • Confirm interactions through reciprocal Co-IP experiments

• Inhibitor Studies:

  • Treat cells with specific inhibitors of MAPK pathway components

  • Assess impact on histone phosphorylation and target gene expression

  • Recommended controls: Use H89 (inhibits MSK1/2) and SB-747651A (MSK1-specific inhibitor)

These experimental approaches will provide insights into how RPS6KA5 connects upstream signaling events to chromatin modification and transcriptional activation. The RPS6KA5 (Ab-564) Antibody is suitable for many of these applications, particularly Western blot and immunoprecipitation protocols.

What methodological approaches can determine RPS6KA5's role in the regulation of inflammatory genes?

RPS6KA5 contributes to the regulation of inflammatory genes, particularly through its interactions with the glucocorticoid receptor NR3C1 and RELA (p65 NF-κB subunit) . To investigate this regulatory role:

• Cytokine Stimulation Experiments:

  • Treat relevant cell types (macrophages, epithelial cells) with pro-inflammatory cytokines (TNF-α, IL-1β)

  • Monitor RPS6KA5 activation using phospho-specific antibodies

  • Analyze nuclear translocation using subcellular fractionation followed by Western blotting with RPS6KA5 (Ab-564) Antibody

  • Protocol recommendation: Use 10-50 ng/ml TNF-α for 15-30 minutes to observe acute RPS6KA5 activation

• RPS6KA5 Knockdown/Knockout Studies:

  • Implement siRNA-mediated knockdown or CRISPR/Cas9 knockout of RPS6KA5

  • Stimulate cells with pro-inflammatory agents

  • Measure expression of inflammatory genes (IL-6, IL-8, TNF-α) by qRT-PCR

  • Analyze NF-κB pathway activation by assessing RELA phosphorylation at Ser276

• Glucocorticoid Response Elements (GRE) Reporter Assays:

  • Construct luciferase reporters containing GRE sequences

  • Compare reporter activity in control versus RPS6KA5-modulated cells

  • Test response to dexamethasone treatment with/without inflammatory stimuli

• Chromatin Occupancy Studies:

  • Perform ChIP using RPS6KA5 (Ab-564) Antibody at promoters of inflammatory genes

  • Compare occupancy in resting, stimulated, and glucocorticoid-treated conditions

  • Combine with ChIP for NR3C1 and RELA to understand temporal occupancy patterns

• Proximity Ligation Assay (PLA):

  • Use RPS6KA5 (Ab-564) Antibody with antibodies against NR3C1 or RELA

  • Visualize and quantify protein-protein interactions in situ

  • Compare interaction patterns under different treatment conditions

• Phosphoproteomics Approach:

  • Implement phosphopeptide enrichment from control and RPS6KA5-inhibited cells

  • Use mass spectrometry to identify differentially phosphorylated proteins in inflammatory signaling pathways

  • Validate key findings with targeted Western blotting

These approaches will help elucidate how RPS6KA5 functions in inflammatory gene regulation, particularly in the context of glucocorticoid-mediated anti-inflammatory effects and NF-κB signaling.

How can RPS6KA5 (Ab-564) Antibody be utilized in studying neurodevelopmental disorders such as Fragile X Syndrome?

Fragile X Syndrome (FXS) has been associated with dysregulation in the MAPK/ERK pathway, where RPS6KA5 plays a significant role . The RPS6KA5 (Ab-564) Antibody can be employed in several methodological approaches to investigate this connection:

• Comparative Expression Analysis:

  • Use Western blotting with RPS6KA5 (Ab-564) Antibody to compare expression levels between control and FXS model systems

  • Analyze both total protein levels and phosphorylation status using appropriate phospho-specific antibodies

  • Quantify results using densitometry normalized to appropriate loading controls

  • Protocol recommendation: Use 30-50 μg total protein for optimal detection

• Immunohistochemistry on Brain Sections:

  • Apply RPS6KA5 (Ab-564) Antibody to brain sections from FXS models and controls

  • Analyze expression patterns in relevant brain regions (hippocampus, prefrontal cortex)

  • Combine with markers for specific cell types (neurons, glia) using multi-label immunofluorescence

  • Recommended dilution: 1:50-1:100 for optimal signal in tissue sections

• Neural Differentiation Studies:

  • Use human neural progenitor cells (hNPCs) from control and FXS patients

  • Monitor RPS6KA5 expression and activation during differentiation

  • Correlate with expression of FMRP (Fragile X Mental Retardation Protein) and downstream targets

  • Assess effects of MAPK pathway modulators on differentiation outcomes

• mGluR-LTD Studies:

  • Investigate RPS6KA5 activation in response to mGluR stimulation in FXS models

  • Use RPS6KA5 (Ab-564) Antibody in conjunction with phospho-specific antibodies

  • Analyze correlation with FMRP-regulated protein synthesis

  • Design time-course experiments (5, 15, 30, 60 minutes post-stimulation)

• MAPK Pathway Interaction Mapping:

  • Use co-immunoprecipitation with RPS6KA5 (Ab-564) Antibody

  • Compare interactome differences between control and FXS models

  • Focus on interactions with FMRP and translation regulatory proteins

  • Validate key interactions with reverse co-IP and proximity ligation assays

• Pharmacological Intervention Studies:

  • Test MAPK pathway modulators (MEK inhibitors, p38 inhibitors)

  • Analyze effects on RPS6KA5 activation and downstream targets

  • Assess impact on FXS-related phenotypes in cellular and animal models

  • Combine with rescue experiments (RPS6KA5 overexpression or knockdown)

These approaches leverage the RPS6KA5 (Ab-564) Antibody to provide insights into the molecular mechanisms underlying FXS and potentially identify therapeutic targets within the MAPK pathway.

What are the common technical issues encountered when using RPS6KA5 (Ab-564) Antibody and how can they be resolved?

When working with RPS6KA5 (Ab-564) Antibody, researchers may encounter several technical challenges. Here are solutions to common issues:

• Weak or No Signal in Western Blot:

  • Possible Causes:

    • Insufficient protein loading

    • Inappropriate antibody dilution

    • Protein degradation

    • Inefficient transfer

  • Solutions:

    • Increase protein loading to 40-50 μg

    • Use a more concentrated antibody dilution (1:500 instead of 1:3000)

    • Add fresh protease and phosphatase inhibitors to lysis buffer

    • Optimize transfer conditions (lower voltage for longer time)

    • Extend primary antibody incubation to overnight at 4°C

• High Background in Immunostaining:

  • Possible Causes:

    • Insufficient blocking

    • Excessive antibody concentration

    • Non-specific binding

  • Solutions:

    • Extend blocking time to 2 hours

    • Use 5% BSA instead of milk for blocking

    • Increase washing steps (5 washes of 5 minutes each)

    • Further dilute antibody (1:200 instead of 1:50)

    • Include 0.1% Triton X-100 in antibody diluent to reduce non-specific binding

• Multiple Bands in Western Blot:

  • Possible Causes:

    • Protein degradation

    • Cross-reactivity

    • Post-translational modifications

  • Solutions:

    • Use fresh samples with complete protease inhibitor cocktail

    • Perform peptide competition assay to identify specific band

    • Run gradient gels for better separation

    • Compare with positive control samples (Jurkat cell extracts)

• Variable Results Between Experiments:

  • Possible Causes:

    • Antibody instability

    • Inconsistent sample preparation

    • Variation in transfer efficiency

  • Solutions:

    • Aliquot antibody to avoid freeze-thaw cycles

    • Standardize lysis and sample preparation protocols

    • Include internal loading controls for normalization

    • Implement a quality control sample across experiments

• Low Signal-to-Noise Ratio in Immunoprecipitation:

  • Possible Causes:

    • Insufficient antibody amount

    • Inadequate washing

    • Non-specific binding to beads

  • Solutions:

    • Increase antibody amount to 3-5 μg per IP reaction

    • Perform more stringent washes with higher salt concentration

    • Pre-clear lysates with protein A/G beads before IP

    • Use crosslinking to covalently attach antibody to beads

By implementing these troubleshooting strategies, researchers can optimize the performance of RPS6KA5 (Ab-564) Antibody across various applications.

What emerging research areas could benefit from application of RPS6KA5 (Ab-564) Antibody?

Several emerging research areas could benefit significantly from the application of RPS6KA5 (Ab-564) Antibody, building upon our current understanding of RPS6KA5 function in cellular signaling:

• Neuroinflammation and Neurodegenerative Diseases:

  • RPS6KA5's role in regulating inflammatory gene expression makes it relevant for studies of neuroinflammation

  • The antibody could be used to investigate RPS6KA5 activation in microglia and astrocytes in models of Alzheimer's, Parkinson's, and MS

  • Correlation studies between RPS6KA5 activity and disease progression could identify new therapeutic targets

• Cancer Epigenetics and Treatment Resistance:

  • RPS6KA5's function in histone modification suggests relevance in cancer epigenetics

  • The antibody could help analyze how RPS6KA5-mediated chromatin changes contribute to treatment resistance

  • Combination studies with epigenetic drugs may reveal synergistic therapeutic approaches

• Single-Cell Signaling Heterogeneity:

  • Adaptation of RPS6KA5 (Ab-564) Antibody for single-cell techniques (mass cytometry, imaging mass cytometry)

  • Investigation of cell-to-cell variation in RPS6KA5 activation within tissues

  • Correlation with cell fate decisions and response to environmental cues

• Stress Response Integration in Cellular Systems:

  • RPS6KA5 responds to various stress stimuli, making it an interesting node in integrated stress responses

  • The antibody could help map how different stressors converge on RPS6KA5 and diverge to different downstream effects

  • Time-resolved studies could reveal the dynamics of these processes

• Immune Checkpoint Regulation:

  • Emerging roles of MAPK signaling in immune checkpoint regulation

  • Potential involvement of RPS6KA5 in modulating T-cell responses through transcriptional regulation

  • Application in immuno-oncology research to understand resistance to checkpoint inhibitors

• RNA-Protein Interactions and Translational Control:

  • Unexplored connections between RPS6KA5 and RNA-binding proteins

  • Potential roles in stress granule formation and mRNA fate determination

  • Integration with RNA-sequencing approaches to identify RPS6KA5-regulated transcripts